NNF

NNF is a 501(c)(3) non-profit organization, so it relies on tax-deductible donations to fund its investment activities. All contributions are reinvested to support additional projects and novel research. The firm does not operate with a traditional limited partner fund structure or charge management fees.

The firm makes direct investments in companies and project-level financing for single assets. Its investing includes traditional biotech start-ups and platform technology companies. NNF does not publicly disclose a portfolio, but its mandate targets products for neurological disorders like autism, epilepsy, and schizophrenia.

NNF's website lists an Executive team, Board of Trustees, Scientific Advisory Board, and Business Advisory Board, but does not publicly name specific executives or investment decision-makers. Without disclosed principals, the precise delegation of investment authority is not verifiable from current public sources.

NNF explicitly positions itself to fill a gap left by disappearing early-stage biotech venture capital firms. It works to make companies attractive to later-stage VCs and pharmaceutical companies by providing initial funding and hands-on management, but it operates as a mission-driven non-profit rather than a for-profit fund.

NNF focuses on very early-stage translational research. It invests in or forms companies that are translating academic research into products, providing the initial capital and operational support that these projects need before they can attract later-stage venture or pharmaceutical investment.